PATIENT SELF-ASSESSMENTS IN ADVANCED PARKINSON'S DISEASE WITHIN UPDRS AND "OFF" TIME SUBGROUPS: COMPARISON OF IPX066 WITH IMEDIATE-RELEASE CARBIDOPA-LEVODOPA

被引：0

作者：

Rubens, R. ^{[1
]}

Rustay, N. R. ^{[1
]}

Khanna, S. ^{[1
]}

Kell, S. ^{[1
]}

Gupta, S. ^{[1
]}

机构：

[1] Impax Labs Inc, Hayward, CA USA

来源：

VALUE IN HEALTH | 2015年 / 18卷 / 03期

关键词：

D O I：

10.1016/j.jval.2015.03.1628

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PND8

引用

页码：A279 / A279

页数：1

共 46 条

[21] Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson's Disease
Hauser, Robert A.
Ellenbogen, Aaron L.
Metman, Leo Verhagen
Hsu, Ann
O'Connell, Martin J.
Modi, Nishit B.
Yao, Hsuan-Ming
Kell, Sherron H.
Gupta, Suneel K.
MOVEMENT DISORDERS, 2011, 26 (12) : 2246 - 2252
[22] Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial
Hauser, Robert A.
Hsu, Ann
Kell, Sherron
Espay, Alberto J.
Sethi, Kapil
Stacy, Mark
Ondo, William
O'Connell, Martin
Gupta, Suneel
LANCET NEUROLOGY, 2013, 12 (04): : 346 - 356
[23] Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis
LeWitt, Peter A.
Metman, Leo Verhagen
Rubens, Robert
Khanna, Sarita
Kell, Sherron
Gupta, Suneel
CLINICAL NEUROPHARMACOLOGY, 2018, 41 (02) : 47 - 55
[24] Comparison of single-dose motor effects of IPX066 to immediate-release carbidopa-levodopa plus entacapone (CLE) in advanced Parkinson's disease (PD) patients
Ellenbogen, A.
Stocchi, F.
Duker, A. P.
Hsu, A.
Khanna, S.
Modi, N.
Rubens, R.
Gupta, S.
MOVEMENT DISORDERS, 2012, 27 : S115 - S116
[25] The effects of weight on adverse event reporting in Parkinson's disease patients treated with IPX066 extended-release carbidopa-levodopa capsules
Kell, S.
O'Connell, M.
Hsu, A.
Silver, D.
Elmer, L.
Gupta, S.
MOVEMENT DISORDERS, 2013, 28 : S146 - S147
[26] The effects of gender on adverse event reporting in Parkinson's disease patients treated with IPX066 extended-release carbidopa-levodopa capsules
Kell, S.
O'Connell, M.
Hsu, A.
Silver, D.
Elmer, L.
Gupta, S.
MOVEMENT DISORDERS, 2013, 28 : S148 - S148
[27] Dose conversion to IPX066 in advanced Parkinson's disease patients treated with carbidopa-levodopa-entacapone
Hsu, A.
Khanna, S.
Kell, S.
Espay, A.
Gil, R.
Singer, C.
Gupta, S.
MOVEMENT DISORDERS, 2013, 28 : S149 - S149
[28] Improvements in activities of daily living and quality of life measures in Hoehn & Yahr subgroups of advanced Parkinson's disease patients following treatment with IPX066, extended-release carbidopa-levodopa
Dhall, Rohit
Gil, Ramon
Lindemulder, Elizabeth
Rubens, Robert
Gupta, Suneel
NEUROLOGY, 2017, 88
[29] Motor function assessment in advanced Parkinson's disease (PD) patients after IPX066 and controlled-release carbidopa-levodopa (CR) using the Unified Parkinson's Disease Rating Scale (UPDRS) and the objective Parkinson's disease measurement (OPDM)
Tetrud, J.
Liang, G.
Ellenbogen, A.
Duker, A.
Hsu, A.
O'Connell, M.
Khanna, S.
Kell, S.
Gupta, S.
MOVEMENT DISORDERS, 2014, 29 : S270 - S270
[30] Conversion of advanced Parkinson's disease patients to IPX066, modified-release levodopa-carbidopa (NUMIENT™), from other levodopa-carbidopa formulations
Gupta, S.
Rubens, R.
Rustay, N.
Khanna, S.
Kell, S.
EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 526 - 526

← 1 2 3 4 5 →